November 14, 2018 6:02pm
The IBB (-2.03%) dived, the Advance/Decline Line (A/DL – 7/36 and 2 flats) degenerated with truncated volume as conviction and confidence sought new bottoms
Investors should be tired of a sector that can’t keep its “pants” up; when was the last time, investors saw a substantial BUY by a CEO of its company stock while down. Share pricing deteriorates as CEO pay jumps to tech level pay-outs (at least they have revenues). What management services are we paying for – as share values continue to decline?
Pre-open indications: 2 HITs and 3 MISS
Quarterly results: Cesca Therapeutics (KOOL +$0.03) and Neuralstem (CUR +$0.002) – before reporting, who wants to eat dog meat share pricing?
Who is defining the metrics for investors?
Some have stated, “I am the “weatherman” of the sector; forecasting and presenting conditions of the sector in a given period.”
WHO is protecting your portfolio’s value?
Daily analytics and metrics:
- The Dow closed down -197.65 points or -0.78% to 25,088.84
- The S&P closed down - 20.60 points or -0.76% to 2,701.58
- The NASDAQ closed down -64.48 points or -0.9% to 7,136.39
From the pre-open newsletter, “the wolves of share pricing are pacing the herd –named, uncertainty, risk and sustainability.”
The advance/decline line scenario of 45 covered companies:
- The open was negative with an A/DL of 15/29 and 1 flat;
- The mid-day was negative with an A/DL of 8/38 and 2 flats;
- The close was negative with an A/DL of 7/36 and 2 flats;
Pre-open indications: 2 HITs and 3 MISS
- Cellectis SA (CLLS) closed down -$1.34 – miss;
- Editas Medicine (EDIT) closed down -$2.08 – hit;
- Regenxbio RGNX) closed down -$3.69 – miss;
- Solid Biosciences (SLDB) closed down -$2.12 – miss;
- Homology Medicines Inc. (FIXX) closed down -$0.04 – hit;
Q3 financial results:
Cesca Therapeutics (KOOL) reported a net loss of $2.6 M, or $0.12 per share (22.1 M weighted average basic and diluted common shares outstanding) as compared to $2.3 M, or $0.24 per share (9.9 million weighted average basic and diluted common shares) for Q3/17 ending the Q with $2.2 M in cash.
Neuralstem (CUR) reported a net loss of $1.8 M, or $0.12 per share (basic), compared to a loss of $100 K, or $0.01 per share (basic), for Q3/17. Cash was reported at $5.7 M
Five (5) key metrics:
… Greatest volume to the downside: SGMO, MDXG, HSGX, XON and VSTM
… Upside volume was weighted to: BTX, KOOL, BLCM, CUR and BCLI
… Weakness ($) to the downside: BLUE (-$3.79), RGNX (-$3.69), ALNY (-$2.24), SLDB (-$2.12) and EDIT (-$2.08)
… Best moves ($) to the upside: BLCM (+$0.16), ADRO (+$0.13), BTX (+$0.06), CLBS (+$0.03) and KOOL (+$0.03)
… The iShares NASDAQ Biotechnology (IBB) closed:
- Wednesday was down -2.03% after NOT indicating in the pre-market;
- Tuesday was down -0.4% after indicating a POSITIVE +0.06% in the pre-market;
- Monday was down -3% after indicating a POSITIVE +0.06% in the pre-market;
- Friday was down -2.21% after indicating a POSITIVE +0.08% in the pre-market;
- Thursday was down -0.77% after NOT indicating in the pre-market;
- Last Wednesday was up +2.3% after NOT indicating in the pre-market;
Sector equities fell on Wednesday as shares of Sangamo therapeutics (SGMO) plunged -$1.25 or -11.94%. An 80% decline in sector shares pressured investor into negativity … that is NOT going to stay the course when they REAP their entry point of initial share price purchase.
What more can one write or say with words - there meaningless ... as reasoning has yet to be defined!
Calling as it is ...
Crispers bounced hard after Tuesday’s ups: CRSP closed down -$1.72 after Tuesday’s+$0.31, EDIT closed down -$2.08 after Tuesday’s +$0.79 and NTLA closed down -$1.25 after Tuesday’s +$0.96; I kept telling many, they had become trading vehicles and they have been!
My beginning month “sucker’s bet financing call of HSGX continues to come to fruition - dived again on Wednesday -$0.04 after Tuesday -$0.04, Monday -$0.03 to $0.48, Friday’s -$0.03 to $0.51, Thursday’s -$0.54 and last Wednesday’s -$0.54 - still going nowhere but, down;
Applied Genetic Technologies (AGTC) closed down -$0.32 to $6.83 after Tuesday’s +$0.10, Monday’s +$0.35 or +5.22% to $7.05, Friday’s $6.70 and Thursday’s $7.01;
I’m STILL FRETTING about VCEL’s upside journey – Wednesday dived -$0.25 after Tuesday’s +$0.41 to $16.44, Monday was down again -$0.08 after Friday was down -$0.49, Thursday’s -$0.49 and last Wednesday’s +$0.44 ($17.09)– I’m still reminded me of the Icarus’ myth!
Tonight’s percentage (%) indicators:
- Review the range of the 7 upside from +0.16% (BCLI) to +9.08% (KOOL) while the 36 downside ranged from -0.2% (FIXX) to -11.94% (SGMO) with 2 flat closes (BSTG and RENE.L).
- 4 out of 7 of the upside had higher (than the 3 month average) volume
- 23 out of the 36 downside experienced greater volume (than the 3 month average).
Wednesday closed NEGATIVE with 36 decliners, 7 advancers and 2 flats;
Tuesday closed NEUTRAL with 21 decliners, 21 advancers and 3 flats;
Monday closed NEGATIVE with 40 decliners, 4 advancers and 1 flat;
Friday closed NEGATIVE with 39 decliners, 6 advancers and 0 flat;
Thursday closed NEGATIVE with 26 decliners, 19 advancers and 1 flat;
Wednesday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;
Tuesday closed NEGATIVE with 22 decliners, 21 advancers and 2 flats;
Monday closed NEGATIVE with 35 decliners, 7 advancers and 3 flats;
Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;
Thursday (11/1) closed POSITIVE with 3 decliners, 42 advancers and 0 flat;
- In 23 sessions in October – there were 17 negative closes and 6 positive closes
- In 19 sessions in September – there were 10 negative closes and 9 positive close;
- In 21 August sessions – 6 had negative and 15 had positive closes
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.